Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 17, 2026, announces the commencement of the fourth tranche of a share buyback programme. The company is a global biopharma firm headquartered in London, UK.
Key Financial Metrics and Capital Allocation
- Buyback Programme Total: £2 billion (announced February 24, 2025).
- Fourth Tranche Value: Up to £0.45 billion.
- Share Price Reference: 31½ pence per Ordinary Share.
- Completion Timeline: Expected to commence February 17, 2026, and complete by April 24, 2026.
- Authority Limit: Within the existing authority to repurchase up to 413,957,879 Ordinary Shares granted at the 2025 Annual General Meeting.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period.
Material Changes and Programme Progress
This announcement marks the final tranche of the £2 billion programme, which is scheduled to conclude by the end of Q2 2026. The first three tranches have been completed as follows:
- Tranche 1: Up to £0.7 billion (commenced February 24, 2025).
- Tranche 2: Up to £0.45 billion (commenced June 4, 2025).
- Tranche 3: Up to £0.3 billion (commenced September 30, 2025).
Management Commentary, Risks, and Unusual Items
Purpose: The programme aims to return excess capital to shareholders, reduce share capital, and enhance earnings per share. Purchased shares will be held as Treasury shares.
Execution: GSK has entered a non-discretionary agreement with BNP Paribas S.A. to execute purchases independently on the London Stock Exchange and/or Cboe Europe Limited. No repurchases will be made in the United States or regarding American Depositary Receipts.
Risks: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties, including those detailed in the 2024 Form 20-F and Q4 2025 results, which may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the total cumulative amount repurchased across all four tranches against the £2 billion target.
- Confirm the impact of the buyback on the company's net debt and liquidity position in the upcoming Q1 2026 results.
- Review the 2024 Form 20-F and Q4 2025 results for specific risk factors mentioned in the cautionary statement.
- Monitor the actual completion date of the fourth tranche relative to the April 24, 2026 target.